Wegovy pre-filled pen on a dark background

Registered medicine

Semaglutide · GLP-1

Wegovy

Registered medicine (EMA)
Developed and studied for weight loss*
Doses from 0.25mg to 2.4mg
Part of a program with lifestyle coaching and guidance

Program from

€200,99/month

Cancel monthly. If you decide not to start after your consultation, you get your money back right away.

Start the questionnaire

Administration

Weekly injection

Dosage

0.25mg – 2.4mg

Active substance

Semaglutide

Manufacturer

Novo Nordisk

Wegovy is registered in Europe for weight management in overweight and obesity. It contains semaglutide, the same active substance as in Ozempic, at the dose studied for weight loss.

How it works

How semaglutide works in your body.

Curbs appetite

Semaglutide mimics GLP-1, the hormone released after eating. Your brain gets the signal sooner: enough.

Fuller for longer

Your stomach empties more slowly, so you stay full longer after a meal and reach for snacks less often.

Studied in trials

The efficacy and safety of semaglutide 2.4 mg were studied in large clinical trials over 68 weeks.*

Building up gently

Your dose grows with you.

Starting low is not a detour but clinical guideline: your body adjusts and side effects stay manageable. You and your doctor set the pace together.

0.25 mg

Weeks 1–4 · adjusting

Your body builds tolerance.

0.5 mg

Weeks 5–8 · building up

Appetite suppression becomes noticeable.

1 mg

From week 9 · maintenance

The steady dose for many clients.

1.7 – 2.4 mg

Optional

Only if a higher dose is needed.

What your medication costs per dose is shown once you have signed up. You get the full overview before you pay anything.

See the full price overview

Already in treatment

Already with another clinic?

In three steps, compare what you pay each month now with what it would be with us. You see the difference straight away.

More than medication

Medication is one part of your program.

Medical intake and oversight, a doctor assesses your situation and follows your progress
Online lifestyle program covering nutrition, sleep, stress and exercise
Personal treatment plan with dosing tailored to you
Discreet home delivery, cooled and fast

See the full program

Compare

Still deciding between treatments?

During the online consultation the doctor advises what suits you best.

This pageSemaglutide

Treatment with Wegovy

Dosage0.25mg – 2.4mg

Program from€ 200,99 /mo

Administrationweekly

Semaglutide

Treatment with Ozempic

Dosage0.25mg – 2mg

Program from€ 199,99 /mo

View Ozempic

Tirzepatide

Treatment with Mounjaro

Dosage2.5mg – 15mg

Program from€ 269,54 /mo

View Mounjaro

FAQ

Frequently asked questions about Wegovy

A BIG-registered doctor reviews your questionnaire and medical situation. In general you qualify with a BMI of 30 or higher, or 27 and up combined with a weight-related health condition. Not sure? Filling in the questionnaire is free of obligation.

Everything that belongs to your program: the medication, doctor consultations, personal coaching, the lifestyle program and cooled shipping. The amount depends on your dose and you can cancel monthly.

The most common side effects are nausea, constipation and diarrhea, especially in the first weeks and around a dose increase. They usually fade as your body adjusts. That is why we build up the dose gently, and you can always reach your doctor if symptoms persist.

That differs per person. The clinical trials of semaglutide 2.4 mg ran for 68 weeks, and in practice many clients work on their goal for 6 to 12 months or longer. You evaluate regularly with your doctor whether continuing makes sense.

Yes. At every evaluation your doctor looks at your progress and any side effects. If things go well, you can move up to a higher dose. If side effects bother you, you stay on a lower step for longer or move a step back.

See all frequently asked questions

Wondering whether treatment suits you?

Fill in the questionnaire, it takes about 10 minutes. A doctor reviews your situation and advises whether the treatment suits you.

Start the questionnaireNo obligation · cancel monthly

* Refers to published clinical trials of semaglutide 2.4 mg over 68 weeks (STEP 1). Results vary per person and are no guarantee. Wegovy is a registered trademark of Novo Nordisk A/S. This page is intended to inform, not to promote medicines. Read the package leaflet before use. A doctor always assesses first whether treatment is medically appropriate.

Blog about medical weight loss

Read our articles about medical weight loss, lifestyle, nutrition, medication, obesity, exercise and healthy living.

Wegovy pil goedgekeurd in Europa: de eerste GLP-1 pil voor gewichtsbeheersing

De Europese Commissie heeft de Wegovy pil goedgekeurd als eerste GLP-1 pil voor gewichtsbeheersing in de EU. Wat is er precies goedgekeurd en wanneer komt de pil naar Nederland?

Orforglipron (Foundayo): wat de GLP-1-pil kan en wanneer hij hier is

De FDA keurde orforglipron op 1 april 2026 goed als Foundayo, de eerste GLP-1-pil zonder eet- of drinkvoorschriften. Wat de ATTAIN-studies laten zien, welke bijwerkingen erbij horen en wanneer het middel in Nederland te verwachten is.

Ontsteking en obesitas: waar start de vicieuze cirkel?

Een diepgaande blik op de complexe relatie tussen obesitas en chronische ontsteking, hoe ze elkaar versterken, en hoe leefstijl en nieuwe behandelingen zoals GLP-1 medicatie deze cirkel kunnen doorbreken.